A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT01015911

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01015911. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Study identification

NCT ID: NCT01015911
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Seagen Inc.; Industry
Enrollment: 58 participants

Conditions and interventions

Conditions

Interventions

SGN-75 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2009 (Type not available)
Primary completion: Nov 2011 (Actual)
Completion: Mar 2012 (Actual)
Last update posted: Dec 18, 2014

2009 – 2012

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294-3300	—
City of Hope National Medical Center	Duarte	California	91010-3000	—
UCLA Medical Center / University of California at Los Angeles	Los Angeles	California	90095-1678	—
Karmanos Cancer Institute / Wayne State University	Detroit	Michigan	48201	—
Mayo Clinic	Rochester	Minnesota	55905	—
Memorial Sloan Kettering Cancer Center	New York	New York	10021	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
MD Anderson Cancer Center / University of Texas	Houston	Texas	77030	—
Seattle Cancer Care Alliance / University of Washington	Seattle	Washington	98109-1023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01015911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2014 · Synced Nov 15, 2026